<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Mesna: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Mesna: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Mesna: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9615" href="/d/html/9615.html" rel="external">see "Mesna: Drug information"</a> and <a class="drug drug_patient" data-topicid="11252" href="/d/html/11252.html" rel="external">see "Mesna: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F193506"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Mesnex</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867478"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Uromitexan</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1048529"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antidote</span>;</li>
<li>
<span class="list-set-name">Antidote, Cyclophosphamide-induced Hemorrhagic Cystitis</span>;</li>
<li>
<span class="list-set-name">Antidote, Ifosfamide-induced Hemorrhagic Cystitis</span>;</li>
<li>
<span class="list-set-name">Chemoprotectant Agent</span></li></ul></div>
<div class="block dop drugH1Div" id="F193531"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dose, frequency, number of doses, and start date may vary by protocol and treatment phase. Refer to individual protocols.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d804e365-f0f2-4ce9-8638-46dca22a1885">Prevention of ifosfamide-induced hemorrhagic cystitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prevention of ifosfamide-induced hemorrhagic cystitis:</b> Mesna dosing schedule should be repeated each day ifosfamide is received according to protocol. If ifosfamide dose is adjusted (decreased or increased), the mesna dose should also be modified to maintain the mesna-to-ifosfamide ratio.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Standard-dose ifosfamide: </i>
<b>Note:</b> ASCO defines standard-dose ifosfamide IV as &lt;2500 mg/m<sup>2</sup>/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19018081']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19018081'])">Ref</a></span>); other pediatric oncology experts suggest ≤2000 mg/m<sup>2</sup>/day in protocols. ASCO defines standard-dose ifosfamide oral as ≤2000 mg/m<sup>2</sup>/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19018081','lexi-content-ref-12065567']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19018081','lexi-content-ref-12065567'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Manufacturer's labeling: IV: Mesna dose is equal to 20% of the ifosfamide dose given for 3 doses: With the ifosfamide dose (hour 0), at hour 4, and at hour 8 after the ifosfamide dose (total daily mesna dose is 60% of the ifosfamide dose). <b>Note:</b> Safety and efficacy not established for ifosfamide doses &gt;2000 mg/m<sup>2</sup>/day.</p>
<p style="text-indent:-2em;margin-left:8em;">Alternate dosing: Limited data available:</p>
<p style="text-indent:-2em;margin-left:10em;">IV:</p>
<p style="text-indent:-2em;margin-left:12em;">Short IV infusion (intermittent): ASCO guidelines: Mesna dose equal to 60% of the ifosfamide dose given in 3 divided doses (20% each) 15 minutes before the ifosfamide dose and at 4 and 8 hours after the start of ifosfamide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19018081']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19018081'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:12em;">Continuous IV infusion: Dosing regimens variable: ASCO guidelines: Mesna dose (as an IV bolus) equal to 20% of the ifosfamide dose, followed by a continuous IV infusion of mesna at 40% of the ifosfamide dose; continue mesna infusion for 12 to 24 hours after completion of ifosfamide infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19018081']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19018081'])">Ref</a></span>). Some centers have used a mesna dose equal to 60% to 100% of the ifosfamide dose as a continuous IV infusion beginning 15 to 30 minutes before the first ifosfamide dose and completed at least 8 hours after the end of the ifosfamide infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11157476']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11157476'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Oral: ASCO guidelines: Total mesna dose equal to 100% of the ifosfamide dose, begin with IV dose equal to 20% for initial dose followed by oral dose at 40% of the ifosfamide dose at 2 and 6 hours after start of ifosfamide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19018081']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19018081'])">Ref</a></span>); <b>Note:</b> Typically, oral doses of mesna are twice the IV dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>High-dose ifosfamide:</i>
<b>Note:</b> ASCO defines high dose as ifosfamide dosage ≥2500 mg/m<sup>2</sup>/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19018081']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19018081'])">Ref</a></span>); other pediatric oncology experts suggest ≥2000 mg/m<sup>2</sup>/day in protocols: Limited data available; dosing regimens variable: IV: ASCO considers evidence for use inadequate and dosing recommendations are not established; more frequent and prolonged mesna administration regimens may be required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19018081']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19018081'])">Ref</a></span>). Some centers have used a mesna dose equal to 100% of the ifosfamide dose as a short IV infusions 5 divided doses (0, 3, 6, 9 and 12) hours after the start of ifosfamide) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gal.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gal.2007'])">Ref</a></span>) or as a continuous IV infusion beginning 15 to 30 minutes before the first ifosfamide dose and completed at least 12 hours after the end of the ifosfamide infusion.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Other dosing strategies have been used in combination with ifosfamide for specific regimens/protocols:</i> Limited data available:</p>
<p style="text-indent:-2em;margin-left:8em;">Mesna continuous IV infusion: Children and Adolescents: IV: 1800 mg/m<sup>2</sup>/day to 5000 mg/m<sup>2</sup>/day as a continuous infusion (100% of the ifosfamide dose), repeated each day ifosfamide is received; see protocols for specific details (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12853357','lexi-content-ref-12972518','lexi-content-ref-11157476']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12853357','lexi-content-ref-12972518','lexi-content-ref-11157476'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Mesna IV bolus followed by continuous IV infusion: Children and Adolescents: IV: 1000 mg/m<sup>2</sup> 1 hour prior to ifosfamide on day 1, followed by 3000 mg/m<sup>2</sup>/day continuous infusion (continuous infusion is 100% of the ifosfamide dose) on days 1, 2, and 3 (with sufficient hydration); administer with subsequent ifosfamide doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16572419']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16572419'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Mesna (20% higher than ifosfamide) continuous IV infusion: Children and Adolescents: IV: 3600 mg/m<sup>2</sup>/day continuous infusion for 4 days (mesna dose is 20% higher than ifosfamide), with hydration, administer with subsequent ifosfamide doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17267204']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17267204'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="339aa7da-d6a6-45a5-bd5c-a546c6de863b">Prevention of cyclophosphamide-induced hemorrhagic cystitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prevention of cyclophosphamide-induced hemorrhagic cystitis:</b> Limited data available: <b>Note:</b> Specific protocols should be consulted for combination regimens with cyclophosphamide. Mesna dosing schedule is typically repeated with each day cyclophosphamide is received; mesna dosing should be adjusted if cyclophosphamide dose is adjusted (decreased or increased) to maintain the mesna-to-cyclophosphamide ratio for the protocol.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Standard (low)-dose cyclophosphamide:</i>
<b>Note:</b> Some pediatric oncology experts have defined as cyclophosphamide dose &lt;1800 mg/m<sup>2</sup>/day in protocols.</p>
<p style="text-indent:-2em;margin-left:8em;">IV: Reported regimens variable: Mesna doses equivalent usually 60% to 100% of the cyclophosphamide daily dose although some protocols have used up to 160%.</p>
<p style="text-indent:-2em;margin-left:10em;">Short IV infusion (intermittent): Mesna dose equal to 60% of the cyclophosphamide dose given in 3 divided doses (0, 4, and 8 hours after the start of cyclophosphamide) has been used by some centers; others have used a mesna dose equal to 100% of the cyclophosphamide dose as short IV infusions in 5 divided doses (0, 3, 6, 9, and 12 hours after the start of cyclophosphamide) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gal.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gal.2007'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Continuous IV infusion: Some centers have used a mesna dose equal to 60% of the cyclophosphamide dose as a continuous IV infusion beginning 15 to 30 minutes before the first cyclophosphamide dose and completed at least 8 hours after the end of the cyclophosphamide infusion.</p>
<p style="text-indent:-2em;margin-left:8em;">Oral: Some centers have used a total mesna dose equal to 100% of the cyclophosphamide dose, begin with IV dose equal to 20% for initial dose followed by oral dose at 40% of the cyclophosphamide dose at 2 and 6 hours after start of cyclophosphamide; <b>Note:</b> Typically, oral doses of mesna are twice the IV dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>High-dose cyclophosphamide:</i>
<b> Note:</b> Some pediatric oncology experts have defined cyclophosphamide dose ≥1800 mg/m<sup>2</sup>/day in protocols: IV: Some centers have used a mesna dose equal to 100% of the cyclophosphamide dose as short IV infusions in 5 divided doses (0, 3, 6, 9, and 12 hours after the start of) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gal.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gal.2007'])">Ref</a></span>) or as a continuous IV infusion beginning 15 to 30 minutes before the first cyclophosphamide dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Other dosing strategies have been used in combination with cyclophosphamide for specific regimens/protocols:</i> Limited data available: HDCAV/IE regimen for Ewing sarcoma: Children and Adolescents: IV: 2100 mg/m<sup>2</sup>/day continuous infusion (mesna dose is equivalent to the cyclophosphamide dose) for 2 days with cyclophosphamide infusion during cycles 1, 2, 3, and 6 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12972518']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12972518'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51129322"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F51129323"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doa drugH1Div" id="F193510"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9615" href="/d/html/9615.html" rel="external">see "Mesna: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Mesna dosing schedule should be repeated each day ifosfamide is administered. If the ifosfamide dose is adjusted (decreased or increased), the mesna dose should also be modified to maintain the mesna-to-ifosfamide ratio. Patients should receive adequate hydration during treatment. Mesna may not prevent hemorrhagic cystitis in all patients; examine urine specimen for hematuria prior to ifosfamide (or cyclophosphamide) treatment; if hematuria &gt;50 RBC/HPF develops, reduce the ifosfamide/cyclophosphamide dose or discontinue.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d804e365-f0f2-4ce9-8638-46dca22a1885">Prevention of ifosfamide-induced hemorrhagic cystitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prevention of ifosfamide-induced hemorrhagic cystitis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Standard-dose ifosfamide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>): <b>IV:</b> Each mesna dose is equal to 20% of the daily ifosfamide dose given for 3 doses: With the ifosfamide dose (hour 0), hour 4, and at hour 8 after the ifosfamide dose (total daily mesna dose is 60% of the daily ifosfamide dose).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral mesna (following IV mesna; for ifosfamide doses ≤2 g/m<sup>2</sup>/day): Mesna dose (IV) is equal to 20% of the daily ifosfamide dose at hour 0, followed by 2 mesna doses (orally), each equal to 40% of the daily ifosfamide dose given 2 and 6 hours after the ifosfamide dose (total daily mesna dose is 100% of the daily ifosfamide dose). <b>Note:</b> If the oral mesna dose is vomited within 2 hours of administration, repeat the oral mesna dose or administer IV mesna.</p>
<p style="text-indent:-2em;margin-left:4em;">Short infusion standard-dose ifosfamide (&lt;2.5 g/m<sup>2</sup>/day): <b>IV:</b> Total mesna dose is equal to 60% of the ifosfamide dose, in 3 divided doses (each mesna dose as 20% of daily ifosfamide dose), given 15 minutes before the ifosfamide dose, and 4 and 8 hours after each dose of ifosfamide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19018081']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19018081'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous infusion standard-dose ifosfamide (&lt;2.5 g/m<sup>2</sup>/day): <b>IV:</b> Mesna dose (as a bolus) is equal to 20% of the daily ifosfamide dose, followed by a continuous infusion of mesna at 40% of the daily ifosfamide dose; continue mesna infusion for 12 to 24 hours after completion of ifosfamide infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19018081']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19018081'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">High-dose ifosfamide (&gt;2.5 g/m<sup>2</sup>/day): Evidence for use is inadequate; more frequent and prolonged mesna administration regimens may be required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19018081']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19018081'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Other dosing strategies used in combination with ifosfamide (off-label dosing):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Mesna continuous infusion:<b> IV:</b> 1.8 g/m<sup>2</sup>/day to 5 g/m<sup>2</sup>/day as a continuous infusion (100% of the ifosfamide dose), repeated each day ifosfamide is received; see protocols for specific details (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12853357','lexi-content-ref-12972518','lexi-content-ref-11157476']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12853357','lexi-content-ref-12972518','lexi-content-ref-11157476'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Mesna bolus followed by continuous infusion: <b>IV:</b> 1 g/m<sup>2</sup> 1 hour prior to ifosfamide on day 1, followed by 3 g/m<sup>2</sup>/day continuous infusion (continuous infusion is 100% of the daily ifosfamide dose) on days 1, 2, and 3 (with sufficient hydration) every 3 weeks for 6 courses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16572419']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16572419'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b60db74c-4833-451a-9f50-2b074b6e2721">Prevention of cyclophosphamide-induced hemorrhagic cystitis in patients with cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prevention of cyclophosphamide-induced hemorrhagic cystitis in patients with cancer (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">HDCAV/IE regimen for Ewing sarcoma: Adults &lt;40 years of age:</p>
<p style="text-indent:-2em;margin-left:6em;">Cycles 1, 2, 3, and 6 (cyclophosphamide-containing regimen): <b>IV:</b> 2.1 g/m<sup>2</sup>/day continuous infusion (mesna dose is equivalent to the daily cyclophosphamide dose) for 2 days with cyclophosphamide infusion during cycles 1, 2, 3, and 6 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12972518']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12972518'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Cycles 4, 5, and 7 (ifosfamide-containing regimen): <b>IV:</b> 1.8 g/m<sup>2</sup>/day continuous infusion (mesna dose is equivalent to the daily ifosfamide dose) for 5 days with ifosfamide infusion during cycles 4, 5, and 7 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12972518']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12972518'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Hyper-CVAD regimen for acute lymphocytic leukemia: <b>IV:</b> 600 mg/m<sup>2</sup>/day continuous infusion (mesna continuous infusion is same total daily dose as cyclophosphamide) on days 1, 2, and 3, beginning with cyclophosphamide and ending 6 hours after the last cyclophosphamide dose during odd-numbered cycles (cycles 1, 3, 5, 7) of an 8-cycle phase (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10653870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10653870'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a758596c-be12-407c-8251-14485c102845">Prevention of cyclophosphamide-induced hemorrhagic cystitis in patients with rheumatic or autoimmune disorders</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prevention of cyclophosphamide-induced hemorrhagic cystitis in patients with rheumatic or autoimmune disorders (off-label use; based on limited data): IV:</b> Each mesna dose is equal to 20% of the daily cyclophosphamide dose given for 3 doses, 15 to 30 minutes prior to cyclophosphamide (hour 0), and 4 and 8 hours after cyclophosphamide (if administering mesna orally, each oral mesna dose is equal to 40% of the daily cyclophosphamide dose, with the first dose administered 2 hours prior to cyclophosphamide, and 4 and 8 hours after cyclophosphamide) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20039416']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20039416'])">Ref</a></span>) <b>or</b> each mesna dose is equal to 20% of the daily cyclophosphamide dose given for 3 doses at 3, 6, and 8 hours following cyclophosphamide each day for 4 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12091370']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12091370'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991986"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied)</p></div>
<div class="block doha drugH1Div" id="F50989222"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied)</p></div>
<div class="block adr drugH1Div" id="F193475"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Mesna alone (frequency not defined):</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Flushing</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Dizziness, drowsiness, headache, hyperesthesia, rigors</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Skin rash</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Anorexia, constipation, diarrhea, dysgeusia (with oral administration), flatulence, nausea, unpleasant taste (with oral administration), vomiting</p>
<p style="text-indent:-2em;margin-left:2em;">Local: Injection site reaction</p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular &amp; skeletal: Arthralgia, back pain</p>
<p style="text-indent:-2em;margin-left:2em;">Ophthalmic: Conjunctivitis</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Cough, flu-like symptoms, pharyngitis, rhinitis</p>
<p style="text-indent:-2em;margin-left:2em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing and/or case reports (mesna alone or in combination): Anaphylaxis, erythema at injection site, hypersensitivity reaction, hypertension, hypotension, increased serum transaminases, increased ST segment on ECG, limb pain, malaise, myalgia, pain at injection site, tachycardia, tachypnea, thrombocytopenia</p></div>
<div class="block coi drugH1Div" id="F193489"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Known hypersensitivity to mesna or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F193473"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic toxicity: Drug rash with eosinophilia and systemic symptoms and bullous/ulcerative skin and mucosal reactions consistent with Stevens-Johnson syndrome or toxic epidermal necrolysis have been reported. The skin and mucosal reactions may be characterized by rash, pruritus, urticaria, erythema, burning sensation, angioedema, periorbital edema, flushing, and stomatitis. Reactions may occur with the first mesna exposure, or after several months of treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hematuria: Monitor urine for hematuria. Severe hematuria despite utilization of mesna may require ifosfamide (or cyclophosphamide) dose reduction or discontinuation. Examine urine specimen for hematuria prior to ifosfamide (or cyclophosphamide) treatment; if hematuria (&gt;50 RBC/HPF) develops, reduce the ifosfamide/cyclophosphamide dose or discontinue; mesna may not prevent hemorrhagic cystitis in all patients. Patients should receive adequate hydration during treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions (including anaphylaxis) have been reported. Reactions may also include fever, hypotension, tachycardia, acute renal impairment, hypoxia, respiratory distress, urticaria, angioedema, signs of disseminated intravascular coagulation, hematologic abnormalities, increased liver enzymes, nausea, vomiting, arthralgia, and myalgia. Reactions may occur with the first mesna exposure, or after several months of treatment. Mesna is a thiol compound; it is unknown if the risk for reaction is increased in patients who have had a reaction to other thiol compounds (eg, amifostine).</p>
<p style="text-indent:-2em;margin-left:4em;">• Ifosfamide/cyclophosphamide toxicities: Mesna is intended for the prevention of hemorrhagic cystitis and will not prevent or alleviate other toxicities associated with ifosfamide or cyclophosphamide.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer’s labeling.</p></div>
<div class="block foc drugH1Div" id="F193483"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mesnex: 100 mg/mL (10 mL) [contains benzyl alcohol, edetate (edta) disodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg/mL (10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mesnex: 400 mg [scored]</p></div>
<div class="block geq drugH1Div" id="F193469"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F16323377"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Mesna Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/mL (per mL): $2.40 - $7.96</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Mesnex Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/mL (per mL): $3.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Mesnex Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $94.31</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867479"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Uromitexan: 100 mg/mL (4 mL, 10 mL, 50 mL) [contains benzyl alcohol, edetate (edta) disodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg/mL (10 mL)</p></div>
<div class="block exp drugH1Div" id="F24888887"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;display:inline">An oral solution may be prepared from mesna solution for injection. Dilute solution for injection to 20 mg/mL or 50 mg/mL with orange or grape syrup. Prior to administration, syrup-diluted solutions may be diluted to a final concentration of 1, 10, or 50 mg/mL with any of the following: Carbonated beverages, apple juice, orange juice, or milk. Mesna injection prepared for oral administration is stable for at least 9 days undiluted in polypropylene syringes and stored at 5°C, 24°C, 35°C; for 7 days when diluted 1:2 or 1:5 with syrups and stored at 24°C in capped tubes; or for 24 hours at 5°C when diluted to 1:2, 1:10, and 1:100 in orange or apple juice, milk, or carbonated beverages. Dilution of mesna with diet or sugar-free preparations has not been evaluated.</p>
<div class="reference">Goren MP, Lyman BA, Li JT. The stability of mesna in beverages and syrup for oral administration. <i>Cancer Chemother Pharmacol</i>. 1991;28(4):298-301.<span class="pubmed-id">1908750</span></div>
</div>
<div class="block admp drugH1Div" id="F52613264"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer orally in tablet form or dilute mesna injection solution for oral use before oral administration to decrease sulfur odor; see Extemporaneous Preparations section. Patients who vomit within 2 hours after taking oral mesna should repeat the dose or receive IV mesna.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Administer as an IV bolus (per manufacturer); current guidelines suggest administration by short IV infusion over 15 to 30 minutes, or by continuous IV infusion (maintain continuous infusion for 12 to 24 after completion of ifosfamide infusion) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19018081']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19018081'])">Ref</a></span>); in some trials, a shorter duration (eg, 8 hours) has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11157476']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11157476'])">Ref</a></span>); refer to specific protocol for administration rate and details.</p></div>
<div class="block adm drugH1Div" id="F193486"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Maintain adequate hydration and urinary output during ifosfamide (or cyclophosphamide) treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Administer as an IV bolus (per manufacturer); may also be administered by short infusion or continuous infusion (maintain continuous infusion for 12 to 24 hours after completion of ifosfamide infusion) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19018081']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19018081'])">Ref</a></span>); refer to specific protocol for administration rate/details.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer orally in tablet formulation; patients who vomit within 2 hours after taking oral mesna should repeat the dose or receive IV mesna. A solution may be prepared from solution for injection by dilution in syrup, juice, carbonate beverages, or milk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1908750']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1908750'])">Ref</a></span>); see Extemporaneously Prepared section.</p></div>
<div class="block sts drugH1Div" id="F193500"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact vials and tablets at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F). Multidose vials may be stored and used for up to 8 days after initial puncture. Solutions diluted for infusion in D5W, NS, D5<sup>1</sup>/<sub>4</sub>NS, D5<sup>1</sup>/<sub>3</sub>NS, D5<sup>1</sup>/<sub>2</sub>NS, or lactated Ringer's and stored at room temperature should be used within 24 hours. According to the manufacturer, mesna and ifosfamide may be mixed in the same bag if the final ifosfamide concentration is ≤50 mg/mL. Solutions of mesna and ifosfamide (1:1) in NS at a concentration of up to 20 mg/mL are stable for 14 days in PVC bags (Zhang 2014). Solutions of mesna (0.5 to 3.2 mg/mL) and cyclophosphamide (1.8 to 10.8 mg/mL) in D5W are stable for 48 hours refrigerated or 6 hours at room temperature (Menard 2003). Mesna injection prepared for oral administration is stable for at least 9 days undiluted in polypropylene syringes and stored at 5°C, 24°C, 35°C; for 7 days when diluted 1:2 or 1:5 with syrups and stored at 24°C in capped tubes; or for 24 hours at 5°C when diluted to 1:2, 1:10, and 1:100 in orange or apple juice, milk, or carbonated beverages (Goren 1991).</p></div>
<div class="block usep drugH1Div" id="F53567742"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Detoxifying agent used as a protectant against ifosfamide-induced hemorrhagic cystitis (Oral: FDA approved in adults; parenteral: FDA approved in pediatric patients [age not specified] and adults); has also been used as a protectant against cyclophosphamide-induced hemorrhagic cystitis </p></div>
<div class="block cyt drugH1Div" id="F13299676"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F193476"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block rep_considerations drugH1Div" id="F53886482"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Verify pregnancy status prior to treatment initiation in patients who could become pregnant. Patients who could become pregnant should use effective contraception during mesna/ifosfamide treatment and for 6 months after the final dose. Patients with partners who could become pregnant should use effective contraception during treatment and for 3 months after the final mesna/ifosfamide dose.</p></div>
<div class="block pri drugH1Div" id="F193492"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Use of mesna to reduce ifosfamide-induced hemorrhagic cystitis in pregnancy has been reported (Lam 2006; Merimsky 1999; Mir 2012).</p>
<p style="text-indent:0em;margin-top:2em;">Mesna injection contains benzyl alcohol as a preservative; exposure to the fetus is expected to be unlikely due to rapid maternal metabolism.</p>
<p style="text-indent:0em;margin-top:2em;">Mesna is administered in combination with cytotoxic agents that may cause fetal harm (refer to specific monographs for additional information).</p></div>
<div class="block mopp drugH1Div" id="F53567741"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Urinalysis, urine color; monitor for hypersensitivity reactions</p></div>
<div class="block pha drugH1Div" id="F193472"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Mesna is oxidized to dimesna in blood, which in turn is reduced in the kidney back to mesna, supplying a free thiol group which binds to and inactivates acrolein, the urotoxic metabolite of ifosfamide and cyclophosphamide</p></div>
<div class="block phk drugH1Div" id="F193488"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: 0.65 ± 0.24 L/kg; distributed to total body water.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 69% to 75%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Rapidly oxidized to mesna disulfide (dimesna) in the intravascular compartment. Mesna and dimesna do not undergo hepatic metabolism.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: Free mesna: 58% (range: 45% to 71%); not affected by food.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Mesna: ~22 minutes; Dimesna: ~70 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Oral: Free mesna: 1.5 to 4 hours; Total mesna: 3 to 7 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (32% as mesna; 33% as dimesna).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F193493"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Uromitexan</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Fada mesna | Mesna delta farma | Mesna Filaxis | Mesna Gobbi | Mesna microsules | Mesna Norgreen | Mesnex | Mestian | Neper | Uromitexan</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Uromitexan</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Uromitexan</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Uromitexan</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Mitexan | Tevamesna</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Uromitexan</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Uromitexan</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Novacarel | Uromitexan | Uroprot</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Uromitexan</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Uromitexan</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Mesna delta farma</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Mesnil | Uromitexan</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Uromitexan</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Uromes | Uromitexan</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Mesna g.e.s | Uromitexan</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Uromitexan</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Mesna EG | Uromitexan</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Uromitexan</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Mesna stada | Uromitexan</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Uromitexan</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Mesna pharmacenter | Uromitexan</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Uromitexan</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Cancena | Uromitexan</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Uromitexan</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Uromitexan</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Uromitexan</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Uromes | Uromitexan</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Uromitexan</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Uromitexan</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">MESNA-cell | Uromitexan</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Uromitexan</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Medaltec | Mesna gi kendrick | Mesna Tecnofarma | Mesnil | Mesodal | Novacarel | Uromes | Uromitexan | Uroprot</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Uromes | Uromitexan</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Uromitexan</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Uromitexan</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Uromitexan</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Uromes</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Uromitexan</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Anti uron | Uromitexan</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Mesnex</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Mesnil</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Uromitexan</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Uromitexan</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Mesna lens | Uromitexan</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Uromitexan</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Uromitexan</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Uromitexan</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Uromitexan</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Uromitexan</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Uromitexan</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Uromitexan</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Uromitexan | Urona</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Mesna delta farma | Mesna Filaxis | Uromitexan | Uronamid</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Uromitexan</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesna-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12853357">
<a name="12853357"></a>Bacci G, Briccoli A, Rocca M, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. <i>Ann Oncol</i>. 2003;14(7):1126-1134.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesna-pediatric-drug-information/abstract-text/12853357/pubmed" id="12853357" target="_blank">12853357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18185020">
<a name="18185020"></a>Basaran M, Bavbek ES, Saglam S, et al. A phase II study of cisplatin, ifosfamide and epirubicin combination chemotherapy in adults with nonmetastatic and extremity osteosarcomas. <i>Oncology</i>. 2007;72(3-4):255-260. doi: 10.1159/000113017.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesna-pediatric-drug-information/abstract-text/18185020/pubmed" id="18185020" target="_blank">18185020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesna-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gal.2007">
<a name="Gal.2007"></a>Gal P, Reed M. Medications. In: Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007: 2955-2999.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28360039">
<a name="28360039"></a>Go RS, Winters JL, Kay NE. How I treat autoimmune hemolytic anemia. <i>Blood</i>. 2017;129(22):2971-2979. doi: 10.1182/blood-2016-11-693689.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesna-pediatric-drug-information/abstract-text/28360039/pubmed" id="28360039" target="_blank">28360039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1908750">
<a name="1908750"></a>Goren MP, Lyman BA, Li JT. The stability of mesna in beverages and syrup for oral administration. <i>Cancer Chemother Pharmacol</i>. 1991;28(4):298-301.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesna-pediatric-drug-information/abstract-text/1908750/pubmed" id="1908750" target="_blank">1908750</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19018081">
<a name="19018081"></a>Hensley ML, Hagerty KL, Kewalramani T, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. <i>J Clin Oncol</i>. 2009;27(1):127-145. doi: 10.1200/JCO.2008.17.2627.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesna-pediatric-drug-information/abstract-text/19018081/pubmed" id="19018081" target="_blank">19018081</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesna-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16572419">
<a name="16572419"></a>Juergens C, Weston C, Lewis I, et al. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. <i>Pediatr Blood Cancer</i>. 2006;47(1):22-29.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesna-pediatric-drug-information/abstract-text/16572419/pubmed" id="16572419" target="_blank">16572419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10653870">
<a name="10653870"></a>Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. <i>J Clin Oncol</i>. 2000;18(3):547-561.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesna-pediatric-drug-information/abstract-text/10653870/pubmed" id="10653870" target="_blank">10653870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16333822">
<a name="16333822"></a>Khaw SL, Downie PA, Waters KD, et al, “Adverse Hypersensitivity Reactions to Mesna as Adjunctive Therapy for Cyclophosphamide,” <i>Pediatr Blood Cancer</i>, 2007, 49(3):341-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesna-pediatric-drug-information/abstract-text/16333822/pubmed" id="16333822" target="_blank">16333822</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12972518">
<a name="12972518"></a>Kolb EA, Kushner BH, Gorlick R, et al. Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. <i>J Clin Oncol</i>. 2003;21(18):3423-3430.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesna-pediatric-drug-information/abstract-text/12972518/pubmed" id="12972518" target="_blank">12972518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17062832">
<a name="17062832"></a>Lam MS. Treatment of Burkitt's lymphoma during pregnancy. <i>Ann</i>
<i>Pharmacother</i>. 2006;40(11):2048-2052. doi: 10.1345/aph.1H289.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesna-pediatric-drug-information/abstract-text/17062832/pubmed" id="17062832" target="_blank">17062832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17267204">
<a name="17267204"></a>Le Deley MC, Guinebretière JM, Gentet JC, et al. SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. <i>Eur J Cancer</i>. 2007;43(4):752-761.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesna-pediatric-drug-information/abstract-text/17267204/pubmed" id="17267204" target="_blank">17267204</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14676103">
<a name="14676103"></a>Mace JR, Keohan ML, Bernardy H, et al, “Crossover Randomized Comparison of Intravenous Versus Intravenous/Oral Mesna in Soft Tissue Sarcoma Treated With High-Dose Ifosfamide,” <i>Clin Cancer Res</i>, 2003, 9(16 Pt 1):5829-34.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesna-pediatric-drug-information/abstract-text/14676103/pubmed" id="14676103" target="_blank">14676103</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14632591">
<a name="14632591"></a>Menard C, Bourguignon C, Schlatter J, Vermerie N. Stability of cyclophosphamide and mesna admixtures in polyethylene infusion bags. <i>Ann Pharmacother</i>. 2003;37(12):1789-1792.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesna-pediatric-drug-information/abstract-text/14632591/pubmed" id="14632591" target="_blank">14632591</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10355581">
<a name="10355581"></a>Merimsky O, Le Chevalier T, Missenard G, et al. Management of cancer in pregnancy: a case of Ewing's sarcoma of the pelvis in the third trimester. <i>Ann Oncol</i>. 1999;10(3):345-350. doi: 10.1023/a:1008235023749.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesna-pediatric-drug-information/abstract-text/10355581/pubmed" id="10355581" target="_blank">10355581</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mesnex.1">
<a name="Mesnex.1"></a>Mesnex (mesna) [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; December 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21769666">
<a name="21769666"></a>Mir O, Berrada N, Domont J, et al. Doxorubicin and ifosfamide for high-grade sarcoma during pregnancy. <i>Cancer Chemother Pharmacol</i>. 2012;69(2):357-367. doi: 10.1007/s00280-011-1707-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesna-pediatric-drug-information/abstract-text/21769666/pubmed" id="21769666" target="_blank">21769666</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20039416">
<a name="20039416"></a>Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review [published correction appears in <i>Arthritis Rheum</i>. 2010;62(8):2555]. <i>Arthritis</i>
<i>Rheum</i>. 2010;62(1):9-21. doi: 10.1002/art.25061.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesna-pediatric-drug-information/abstract-text/20039416/pubmed" id="20039416" target="_blank">20039416</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11157476">
<a name="11157476"></a>Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. <i>Blood</i>. 2001;97(3):616-623.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesna-pediatric-drug-information/abstract-text/11157476/pubmed" id="11157476" target="_blank">11157476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12091370">
<a name="12091370"></a>Moyo VM, Smith D, Brodsky I, Crilley P, Jones RJ, Brodsky RA. High-dose cyclophosphamide for refractory autoimmune hemolytic anemia. <i>Blood</i>. 2002;100(2):704-706. doi: 10.1182/blood-2002-01-0087.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesna-pediatric-drug-information/abstract-text/12091370/pubmed" id="12091370" target="_blank">12091370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2107997">
<a name="2107997"></a>Schoenike SE and Dana WJ, “Ifosfamide and Mesna,” <i>Clin Pharm</i>, 1990, 9(3):179-91.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesna-pediatric-drug-information/abstract-text/2107997/pubmed" id="2107997" target="_blank">2107997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12065567">
<a name="12065567"></a>Schuchter LM, Hensley ML, Meropol NJ, Winer EP; American Society of Clinical Oncology Chemotherapy and Radiotherapy Expert Panel. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. <i>J Clin Oncol</i>. 2002;20(12):2895-2903. doi: 10.1200/JCO.2002.04.178.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesna-pediatric-drug-information/abstract-text/12065567/pubmed" id="12065567" target="_blank">12065567</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9540174">
<a name="9540174"></a>Siu LL and Moore MJ, “Use of Mesna to Prevent Ifosfamide-Induced Urotoxicity,” <i>Support Care Cancer</i>, 1998, 6(2):144-54.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesna-pediatric-drug-information/abstract-text/9540174/pubmed" id="9540174" target="_blank">9540174</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23512269">
<a name="23512269"></a>Zhang Y, Kawedia JD, Myers AL, et al. Physical and chemical stability of high-dose ifosfamide and mesna for prolonged 14-day continuous infusion. <i>J Oncol Pharm Pract</i>. 2014;20(1):51-57. doi: 10.1177/1078155213478284.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mesna-pediatric-drug-information/abstract-text/23512269/pubmed" id="23512269" target="_blank">23512269</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12585 Version 211.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
